---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031978"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-10-05T12:30:21+00:00"
generated_at: "2026-10-12T14:46:07.649943+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Moleculin Biotech 8-K cites Oct 5, 2026 investor presentation; exhibit content not included

## Summary
- Moleculin Biotech (MBRX) said it is using an attached corporate presentation posted on its website, dated October 5, 2026, per the filing signed by Jonathan P. Foster.
- Exhibit 99.1 contains no presentation text, slides, data tables, or figures - only the exhibit title - so no clinical, pipeline, or financial updates are available in this filing.
- No earnings, guidance, trial results, financing terms, or partnership details appear anywhere in the filing body or the appended exhibit.
- Investors seeking the actual corporate presentation content must retrieve it directly from the company's website; it cannot be summarized from this document.

## SEC filing metadata
- accession: 0001437749-26-031978
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-10-05T12:30:21+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031978/0001437749-26-031978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031978/mbrx20260928c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031978
- JSON: https://secwatch.observer/filing/0001437749-26-031978.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.